Can You Lose Weight on Semaglutide — and How Much?

Step 1, what semaglutide does in your body from the first dose

Understanding how semaglutide produces weight loss starts with the GLP-1 receptor. GLP-1 (glucagon-like peptide-1) is a hormone your gut releases naturally after eating. It travels to the brain's appetite centres and signals that you have had enough. Semaglutide mimics that signal continuously, so the brain receives a sustained message of fullness even before a meal is finished.

At the same time, the medicine slows gastric emptying, food moves from the stomach into the small intestine more gradually. That mechanical effect means blood glucose rises more steadily after eating and physical fullness lasts longer. Together, the two actions reduce the number of calories most people feel comfortable eating without any sense of white-knuckling through hunger. Our page on how semaglutide works to produce weight loss covers the receptor biology in more detail if you want to go deeper.

The starting dose in the licensed schedule is 0.25mg weekly. That figure is not a therapeutic weight-loss dose, its job is to let your system adjust gradually, reducing the likelihood of nausea. The dose is increased in steps, typically every four weeks, under prescriber guidance, up to the 2.4mg maintenance dose for Wegovy. Patients who are eligible for the newer 7.2mg pen may reach a higher ceiling still, subject to clinical assessment, and if you are considering a branded alternative you can read more about Freya semaglutide to see how it compares.

Step 2, the timeline: when weight loss actually happens on semaglutide

A question our prescribers field most weeks is when results actually show up. The honest answer is: gradually, and not linearly. Some people notice appetite changes within the first two weeks. On the scale, meaningful loss tends to become visible once the dose rises above the starter level, usually from weeks four to eight onwards.

The clearest way to read the evidence is through the STEP 1 trial, published in the New England Journal of Medicine: the 15% average was measured at 68 weeks, so the full picture takes well over a year to emerge. Progress in the first three months looks modest compared with the total; in the final months, it can feel like it has plateaued. That is normal, the medicine is still working even when the scale barely moves for a fortnight. Our more detailed breakdown of when weight loss tends to occur on Wegovy maps the timeline week by week.

One practical note: if you are planning to start and you are timing around payday or a holiday, the clinical review happens the same day you submit your consultation, so the gap between starting the process and receiving your first pen is typically just one working day rather than weeks.

Step 3 (what makes the difference between average and above-average results

The 15% average in STEP 1 is exactly that) an average across a diverse population. Some participants lost considerably more; others less. Several factors appear to influence where on that range a person lands, and most of them are modifiable.

Diet remains the foundation. Semaglutide lowers appetite; it does not lower the caloric density of what you choose to eat. People who use the reduced hunger as a prompt to shift towards protein-rich, higher-fibre meals tend to see stronger results and preserve more lean muscle. The NHS healthy weight guidance gives a practical starting framework. Physical activity, particularly resistance training, also matters, not for calorie arithmetic alone, but because muscle mass supports the metabolic rate that weight loss would otherwise reduce.

Adherence to the titration schedule and staying on treatment long enough also predict outcomes. People who stop semaglutide typically regain a significant portion of lost weight within a year, which is why the prescriber relationship (reviewing each repeat order before it is dispensed) exists to support continuity rather than just gatekeeping. For a fuller guide on how to lose weight effectively on Wegovy, including diet and activity tips specific to treatment, that page covers the practical detail.

Step 4, who semaglutide is licensed for, and what to expect from the process

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, raised cholesterol or prediabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. Meeting the BMI number is the starting point, not a guarantee, a prescriber considers your full health picture, including any medicines you already take and conditions that would make GLP-1 treatment unsuitable.

On the NHS, access is via specialist weight management services under NICE guidance (TA875), and waiting lists in many areas are long. Privately, a regulated online pharmacy like ours can provide access without a referral, provided the clinical assessment confirms suitability. The semaglutide weight-loss overview explains the full eligibility picture, and the Wegovy access guide walks through both NHS and private routes so you can decide which path makes sense for your situation.

If you would like a clinical team to assess whether semaglutide is right for you, the consultation is free and reviewed the same day by a GPhC-registered prescriber. Start your free consultation to find out whether you are eligible.